Across TCGA pan-cancer cohorts, SFT2D2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SFT2D2 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher SFT2D2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SFT2D2 expression acts as an unfavorable survival marker.
COAD, LUSC, and LUAD are the cancer types where SFT2D2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.